Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B

MP. Bonaca, DA. Morrow, BA. Bergmark, DD. Berg, JAC. Lima, U. Hoffmann, Y. Kato, MT. Lu, J. Kuder, SA. Murphy, J. Spinar, T. Oude Ophuis, RG. Kiss, J. Lopez-Sendon, O. Averkov, SB. Wheatcroft, J. Kubica, J. Carlos Nicolau, RHM. Furtado, L....

. 2022 ; 146 (12) : 907-916. [pub] 20220830

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024369

BACKGROUND: High-density lipoprotein plays a key role in reverse cholesterol transport. In addition, high-density lipoprotein particles may be cardioprotective and reduce infarct size in the setting of myocardial injury. Lecithin-cholesterol acyltransferase is a rate-limiting enzyme in reverse cholesterol transport. MEDI6012 is a recombinant human lecithin-cholesterol acyltransferase that increases high-density lipoprotein cholesterol. Administration of lecithin-cholesterol acyltransferase has the potential to reduce infarct size and regress coronary plaque in acute ST-segment-elevation myocardial infarction. METHODS: REAL-TIMI 63B (A Randomized, Placebo‐controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction) was a phase 2B multinational, placebo-controlled, randomized trial. Patients with ST-segment-elevation myocardial infarction within 6 hours of symptom onset and planned for percutaneous intervention were randomly assigned 2:1 to MEDI6012 (2- or 6-dose regimen) or placebo and followed for 12 weeks. The primary outcome was infarct size as a percentage of left ventricular mass by cardiac MRI at 10 to 12 weeks, with the primary analysis in patients with TIMI Flow Grade 0 to 1 before percutaneous intervention who received at least 2 doses of MEDI6012. The secondary outcome was change in noncalcified plaque volume on coronary computed tomographic angiography from baseline to 10 to 12 weeks with the primary analysis in patients who received all 6 doses of MEDI6012. RESULTS: A total of 593 patients were randomly assigned. Patients were a median of 62 years old, 77.9% male, and 95.8% statin naive. Median time from symptom onset to randomization was 146 (interquartile range [IQR], 103-221) minutes and from hospitalization to randomization was 12.7 (IQR, 6.6-24.0) minutes, and the first dose of drug was administered a median of 8 (IQR, 3-13) minutes before percutaneous intervention. The index myocardial infarction was anterior in 69.6% and TIMI Flow Grade 0 to 1 in 65.1% of patients. At 12 weeks, infarct size did not differ between treatment groups (MEDI6012: 9.71%, IQR 4.79-16.38; placebo: 10.48%, [IQR, 4.92-16.61], 1-sided P=0.79. There was also no difference in noncalcified plaque volume (geometric mean ratio, 0.96 [95% CI, NA-1.10], 1-sided P=0.30). There was no significant difference in treatment emergent serious adverse events. CONCLUSIONS: Administration of MEDI6012 in patients with acute ST-segment-elevation myocardial infarction did not result in a significant reduction in infarct size or noncalcified plaque volume at 12 weeks. MEDI6012 was well tolerated with no excess in overall serious adverse events. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03578809.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024369
003      
CZ-PrNML
005      
20221031101238.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/CIRCULATIONAHA.122.059325 $2 doi
035    __
$a (PubMed)36039762
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bonaca, Marc P $u CPC Clinical Research, Department of Medicine, University of Colorado Anschutz School of Medicine, Aurora (M.P.B.) $1 https://orcid.org/0000000298603584
245    10
$a Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B / $c MP. Bonaca, DA. Morrow, BA. Bergmark, DD. Berg, JAC. Lima, U. Hoffmann, Y. Kato, MT. Lu, J. Kuder, SA. Murphy, J. Spinar, T. Oude Ophuis, RG. Kiss, J. Lopez-Sendon, O. Averkov, SB. Wheatcroft, J. Kubica, J. Carlos Nicolau, RHM. Furtado, L. Abuhatzira, B. Hirshberg, SA. Omar, AL. Vavere, YT. Chang, RT. George, MS. Sabatine
520    9_
$a BACKGROUND: High-density lipoprotein plays a key role in reverse cholesterol transport. In addition, high-density lipoprotein particles may be cardioprotective and reduce infarct size in the setting of myocardial injury. Lecithin-cholesterol acyltransferase is a rate-limiting enzyme in reverse cholesterol transport. MEDI6012 is a recombinant human lecithin-cholesterol acyltransferase that increases high-density lipoprotein cholesterol. Administration of lecithin-cholesterol acyltransferase has the potential to reduce infarct size and regress coronary plaque in acute ST-segment-elevation myocardial infarction. METHODS: REAL-TIMI 63B (A Randomized, Placebo‐controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction) was a phase 2B multinational, placebo-controlled, randomized trial. Patients with ST-segment-elevation myocardial infarction within 6 hours of symptom onset and planned for percutaneous intervention were randomly assigned 2:1 to MEDI6012 (2- or 6-dose regimen) or placebo and followed for 12 weeks. The primary outcome was infarct size as a percentage of left ventricular mass by cardiac MRI at 10 to 12 weeks, with the primary analysis in patients with TIMI Flow Grade 0 to 1 before percutaneous intervention who received at least 2 doses of MEDI6012. The secondary outcome was change in noncalcified plaque volume on coronary computed tomographic angiography from baseline to 10 to 12 weeks with the primary analysis in patients who received all 6 doses of MEDI6012. RESULTS: A total of 593 patients were randomly assigned. Patients were a median of 62 years old, 77.9% male, and 95.8% statin naive. Median time from symptom onset to randomization was 146 (interquartile range [IQR], 103-221) minutes and from hospitalization to randomization was 12.7 (IQR, 6.6-24.0) minutes, and the first dose of drug was administered a median of 8 (IQR, 3-13) minutes before percutaneous intervention. The index myocardial infarction was anterior in 69.6% and TIMI Flow Grade 0 to 1 in 65.1% of patients. At 12 weeks, infarct size did not differ between treatment groups (MEDI6012: 9.71%, IQR 4.79-16.38; placebo: 10.48%, [IQR, 4.92-16.61], 1-sided P=0.79. There was also no difference in noncalcified plaque volume (geometric mean ratio, 0.96 [95% CI, NA-1.10], 1-sided P=0.30). There was no significant difference in treatment emergent serious adverse events. CONCLUSIONS: Administration of MEDI6012 in patients with acute ST-segment-elevation myocardial infarction did not result in a significant reduction in infarct size or noncalcified plaque volume at 12 weeks. MEDI6012 was well tolerated with no excess in overall serious adverse events. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03578809.
650    12
$a infarkt myokardu přední stěny $7 D056988
650    _2
$a cholesterol $7 D002784
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a statiny $x terapeutické užití $7 D019161
650    _2
$a lecitiny $x terapeutické užití $7 D054709
650    _2
$a lipoproteiny HDL $x terapeutické užití $7 D008075
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a lecitincholesterolacyltransferasa $x terapeutické užití $7 D007862
650    12
$a infarkt myokardu s elevacemi ST úseků $x diagnostické zobrazování $x farmakoterapie $7 D000072657
650    _2
$a cholesterolacyltransferasa $x terapeutické užití $7 D002785
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Morrow, David A $u TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (D.A.M., B.A.B., D.D.B., J. Kuder, S.A.M., M.S.S.) $1 https://orcid.org/0000000295895382
700    1_
$a Bergmark, Brian A $u TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (D.A.M., B.A.B., D.D.B., J. Kuder, S.A.M., M.S.S.) $1 https://orcid.org/0000000343607606
700    1_
$a Berg, David D $u TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (D.A.M., B.A.B., D.D.B., J. Kuder, S.A.M., M.S.S.) $1 https://orcid.org/0000000203665492
700    1_
$a Lima, Joao A C $u Division of Cardiology, Johns Hopkins University, Baltimore, MD (J.A.C.L., Y.K.) $1 https://orcid.org/0000000187566995
700    1_
$a Hoffmann, Udo $u Internal Cardioangiology Department, St. Ann University Hospital and Masaryk University, Brno, Czechia (J.S.)
700    1_
$a Kato, Yoko $u Division of Cardiology, Johns Hopkins University, Baltimore, MD (J.A.C.L., Y.K.) $1 https://orcid.org/0000000243281987
700    1_
$a Lu, Michael T $u Cardiovascular Imaging Research Center, Massachusetts General Hospital and Harvard Medical School, Boston (U.H., M.T.L.) $1 https://orcid.org/0000000346969610
700    1_
$a Kuder, Julia $u TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (D.A.M., B.A.B., D.D.B., J. Kuder, S.A.M., M.S.S.)
700    1_
$a Murphy, Sabina A $u TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (D.A.M., B.A.B., D.D.B., J. Kuder, S.A.M., M.S.S.)
700    1_
$a Spinar, Jindrich $u Internal Cardioangiology Department, St. Ann University Hospital and Masaryk University, Brno, Czechia (J.S.)
700    1_
$a Oude Ophuis, Ton $u Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands (T.O.O.)
700    1_
$a Kiss, Róbert G $u Department of Cardiology, Military Hospital, Budapest, Hungary (R.G.K.)
700    1_
$a Lopez-Sendon, Jose $u IdiPaz Research Institute, Hospital Universitario La Paz, UAM, Madrid, Spain (J.L.-S.) $1 https://orcid.org/0000000208719197
700    1_
$a Averkov, Oleg $u Pirogov Russian National Research Medical University, Moscow (O.A.)
700    1_
$a Wheatcroft, Stephen B $u Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, UK (S.B.W.)
700    1_
$a Kubica, Jacek $u Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland (J. Kubica)
700    1_
$a Carlos Nicolau, Jose $u Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Brazil (J.C.N., R.H.M.F.) $1 https://orcid.org/0000000296803689
700    1_
$a Furtado, Remo H M $u Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Brazil (J.C.N., R.H.M.F.) $u Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil (R.H.M.G.) $1 https://orcid.org/0000000346391003
700    1_
$a Abuhatzira, Liron $u Horizon Therapeutics, Gaithersburg, MD (L.A.)
700    1_
$a Hirshberg, Boaz $u Regio Biosciences, Rockville, MD (B.H.)
700    1_
$a Omar, Sami A $u Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD (S.A.O., A.L.V., Y.-T.C., R.T.G.)
700    1_
$a Vavere, Andrea L $u Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD (S.A.O., A.L.V., Y.-T.C., R.T.G.)
700    1_
$a Chang, Yi-Ting $u Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD (S.A.O., A.L.V., Y.-T.C., R.T.G.)
700    1_
$a George, Richard T $u Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD (S.A.O., A.L.V., Y.-T.C., R.T.G.) $1 https://orcid.org/0000000348170378
700    1_
$a Sabatine, Marc S $u TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (D.A.M., B.A.B., D.D.B., J. Kuder, S.A.M., M.S.S.) $1 https://orcid.org/0000000206913359
773    0_
$w MED00001091 $t Circulation $x 1524-4539 $g Roč. 146, č. 12 (2022), s. 907-916
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36039762 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031101235 $b ABA008
999    __
$a ok $b bmc $g 1854216 $s 1175659
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 146 $c 12 $d 907-916 $e 20220830 $i 1524-4539 $m Circulation (New York, N.Y.) $n Circulation (New York) $x MED00001091
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace